{"analyses":[{"groupIds":["OG000","OG001","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"= 0.38","statisticalMethod":"Kruskal-Wallis"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"78.1","value":"5.0"},{"groupId":"OG001","lowerLimit":"0.7","upperLimit":"602.1","value":"24.3"},{"groupId":"OG002","lowerLimit":"6.8","upperLimit":"182.6","value":"117.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"13"}],"units":"Participants"}],"description":"Simultaneously with QCT-measurements coronary calcification was be assessed. Agatston score is a score based on the extent of coronary artery calcification calculated on the amount of plaque observed in a CT scan. A score of zero indicates absence of coronary calcium, 1-10: minimal calcification, 11-100 mild calcification, 101-400 moderate calcification, \\>400 severe calcification.\n\nThus the score increases with increasing level of calcification in the coronary vessels.","dispersionType":"Inter-Quartile Range","groups":[{"description":"15 subjects were treated with combined 60mg denosumab every six months, 30 mg cinacalcet daily and 50 micrograms vitamin-D3 daily.","id":"OG000","title":"Combined Treatment."},{"description":"16 subjects received 60 mg denosumab every six months, placebo and 50 micrograms vitamin-D daily.","id":"OG001","title":"Denosumab Monotherapy"},{"description":"15 subjects will receive a saline injection every six months(blinded), placebo-tablets and 50 micrograms vitamin-D daily.","id":"OG002","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"Some participant from the combined and placebo groups could not be included in the analysis because they had coronary stents.","reportingStatus":"POSTED","timeFrame":"Baseline, one year","title":"Median Agatstons Score Final","type":"SECONDARY","unitOfMeasure":"score on a scale"}